Welcome to our dedicated page for Precipio news (Ticker: PRPO), a resource for investors and traders seeking the latest updates and insights on Precipio stock.
Precipio, Inc. reports developments from its specialty cancer diagnostics business, which focuses on diagnostic products and services for cancer, including hematologic malignancies. Company updates commonly address performance in the Pathology Services Division and Products Division, customer and laboratory workflow trends, shareholder update calls, and balance sheet actions tied to debt, warrants, and common-stock financing arrangements.
Precipio news also covers its proprietary diagnostic technologies, including the Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia, study publications, scientific meeting presentations, and collaborations involving clinical laboratories and cancer centers. Operational disclosures may include cybersecurity response, service continuity, and the company’s use of laboratory-developed technologies that are validated clinically and commercialized for the broader laboratory market.
Precipio, a specialty cancer diagnostics company, urgently requests shareholders to vote by today, June 12, 2024, to ensure a quorum for their Annual Shareholders Meeting scheduled for tomorrow, June 13, 2024. As of now, only 44% of shares have been voted, and at least 50% is needed. Failure to achieve this quorum could result in rescheduling, which may cost the company up to $100,000, compared to the less than $5,000 for the current meeting. Shareholders are urged to instruct their brokers to vote by 11 p.m. Eastern Time to avoid these potential costs.
Precipio, a specialty cancer diagnostics company, provided a business update addressing several key areas. In Q3 2023, the pathology division surpassed its $15M annual revenue breakeven point but faced setbacks in the following quarter. The company has rectified operational issues and expects to breach the breakeven point again by Q3 2024. On the products side, delays due to technical and supply chain issues have been resolved, with significant customer onboarding anticipated to drive revenue growth. The company was impacted by the Change Healthcare hacking but expects normal operations to resume by Q3 2024. A recent FDA ruling on Laboratory Developed Tests (LDTs) will require Precipio to submit its products for FDA approval over the next four years, at an estimated cost of $250,000. Precipio's CEO expressed confidence in reaching breakeven this year and highlighted an upcoming shareholder meeting on June 13, 2024.
Precipio, Inc. (NASDAQ: PRPO) has secured a $500K short-term loan facility to address cash collection delays due to Change Healthcare's cybersecurity attack. The loan will help manage any temporary cashflow deficits impacting the company's Diagnostic Services division. While the cybersecurity incident affected CH's cash reserves, Precipio's Products division remains unaffected. The loan allows flexibility in borrowing and repayment, ensuring operational liquidity.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.